• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

便秘负担:不仅仅关注排便情况。

Burden of Constipation: Looking Beyond Bowel Movements.

机构信息

Mayo Clinic Scottsdale, Scottsdale, Arizona, USA.

University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.

出版信息

Am J Gastroenterol. 2022 Apr 1;117(4S):S2-S5. doi: 10.14309/ajg.0000000000001708.

DOI:10.14309/ajg.0000000000001708
PMID:35354769
Abstract

Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are associated with significant social and economic burdens. To address these burdens, a deeper understanding of their root causes is required. A discrepancy exists between patients' and healthcare providers' (HCPs) perceptions of constipation symptoms and the impact of symptoms associated with CIC and IBS-C. Compared with the HCPs' perceptions of patients' symptoms, a greater percentage of patients report acceptance and feeling in control of their CIC or IBS-C symptoms. Unfortunately, only one-third of individuals with CIC or IBS-C formally consult an HCP about their constipation. Fewer than half take medications, and these are generally over-the-counter therapies rather than prescription therapies. For those who seek help, only one-fifth feel that their constipation symptoms are well managed. Notable sex and cultural differences exist regarding individuals consulting their HCP about constipation. Many individuals with CIC and IBS-C remain inadequately managed and unduly affected, contributing to the high social and economic burden of these conditions.

摘要

慢性特发性便秘(CIC)和便秘型肠易激综合征(IBS-C)与重大的社会和经济负担相关。为了应对这些负担,需要深入了解其根本原因。患者和医疗保健提供者(HCP)对便秘症状的认知以及与 CIC 和 IBS-C 相关症状的影响之间存在差异。与 HCP 对患者症状的认知相比,更多的患者报告对其 CIC 或 IBS-C 症状的接受程度和控制感。不幸的是,只有三分之一的 CIC 或 IBS-C 患者正式向 HCP 咨询其便秘问题。服用药物的人数不到一半,而且这些药物通常是非处方治疗药物,而不是处方治疗药物。对于那些寻求帮助的人,只有五分之一的人认为他们的便秘症状得到了很好的控制。在就便秘问题咨询 HCP 方面,存在明显的性别和文化差异。许多 CIC 和 IBS-C 患者的治疗仍不充分,且受到过度影响,导致这些疾病的社会和经济负担很高。

相似文献

1
Burden of Constipation: Looking Beyond Bowel Movements.便秘负担:不仅仅关注排便情况。
Am J Gastroenterol. 2022 Apr 1;117(4S):S2-S5. doi: 10.14309/ajg.0000000000001708.
2
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法:聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
3
A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.一项基于社区队列的慢性特发性便秘与便秘型肠易激综合征直接医疗服务提供者医疗成本的病例对照比较。
J Med Econ. 2017 Mar;20(3):273-279. doi: 10.1080/13696998.2016.1253584. Epub 2016 Nov 10.
4
The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.以便秘为主的肠易激综合征和慢性特发性便秘的范围:美国评估症状、就医情况和疾病负担的调查
Am J Gastroenterol. 2015 Apr;110(4):580-7. doi: 10.1038/ajg.2015.67. Epub 2015 Mar 17.
5
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire.更好地理解和认识便秘型肠易激综合征(BURDEN IBS-C)患者的脱节、体验和需求研究:在线问卷结果。
Adv Ther. 2018 Jul;35(7):967-980. doi: 10.1007/s12325-018-0733-x. Epub 2018 Jun 26.
6
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性:系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
7
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).使用确定性链接的行政索赔和患者报告数据对便秘型肠易激综合征和慢性特发性便秘患者进行综合评估:慢性便秘和肠易激综合征 C 型治疗和结局真实世界研究平台(CONTOR)。
J Med Econ. 2020 Oct;23(10):1072-1083. doi: 10.1080/13696998.2020.1799816. Epub 2020 Aug 11.
8
The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire.更好地理解和认识慢性特发性便秘患者的脱节、经历和需求(BURDEN-CIC)研究:在线问卷的结果。
Adv Ther. 2017 Dec;34(12):2661-2673. doi: 10.1007/s12325-017-0633-5. Epub 2017 Nov 6.
9
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.新型促动力和促分泌剂在慢性特发性便秘和便秘型肠易激综合征治疗中的应用。
Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14.
10
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.

引用本文的文献

1
Effects of Three Microbiome-Based Therapies on Loperamide-Induced Constipation in Mice by Restoring Intestinal Motility and Modulating the Intestinal Microbiota.三种基于微生物群的疗法通过恢复肠道蠕动和调节肠道微生物群对小鼠洛哌丁胺诱导的便秘的影响。
Probiotics Antimicrob Proteins. 2025 Aug 27. doi: 10.1007/s12602-025-10732-x.
2
Fecal microbiota transplantation for chronic constipation: a systematic review and meta-analysis of clinical efficacy, safety, and microbial dynamics.粪便微生物群移植治疗慢性便秘:临床疗效、安全性及微生物动态变化的系统评价和荟萃分析
Front Microbiol. 2025 Jul 31;16:1604571. doi: 10.3389/fmicb.2025.1604571. eCollection 2025.
3
Effects of Dietary Fiber Supplementation on Chronic Constipation in the Elderly: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
膳食纤维补充剂对老年人慢性便秘的影响:一项随机对照试验的系统评价和荟萃分析
Foods. 2025 Jun 30;14(13):2315. doi: 10.3390/foods14132315.
4
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.普卡那肽在中国功能性便秘患者中的疗效与安全性:一项III期多中心、随机、双盲、安慰剂对照试验
Drugs. 2025 Jun 26. doi: 10.1007/s40265-025-02205-w.
5
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation.美国普芦卡必利起始治疗前后慢性特发性便秘患者的经济负担
Gastro Hep Adv. 2025 Mar 24;4(7):100664. doi: 10.1016/j.gastha.2025.100664. eCollection 2025.
6
Factors Influencing the Severity of Urinary and Defecatory Dysfunction Among the Middle-Aged and Older Adult Chinese Population: Longitudinal Study of a 5-Wave Survey Cohort.影响中国中老年人群泌尿和排便功能障碍严重程度的因素:一项5波调查队列的纵向研究
JMIR Aging. 2025 May 26;8:e70541. doi: 10.2196/70541.
7
Negative association between body roundness index and constipation: insights from NHANES.身体圆润度指数与便秘之间的负相关关系:来自美国国家健康与营养检查调查(NHANES)的见解
J Health Popul Nutr. 2025 May 9;44(1):149. doi: 10.1186/s41043-025-00886-3.
8
Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population.便秘型肠易激综合征或慢性特发性便秘患者开始口服治疗后的医疗保健利用情况及护理费用:美国医疗保险人群的真实世界分析
Adv Ther. 2025 May;42(5):2500-2512. doi: 10.1007/s12325-025-03163-1. Epub 2025 Mar 28.
9
An overlap-weighted analysis on the association of constipation symptoms with disease progression and survival in amyotrophic lateral sclerosis: a nested case-control study.肌萎缩侧索硬化症中便秘症状与疾病进展及生存关联的重叠加权分析:一项巢式病例对照研究
Ther Adv Neurol Disord. 2025 Jan 9;18:17562864241309811. doi: 10.1177/17562864241309811. eCollection 2025.
10
Cost-Effectiveness of Vibrant System vs. Linaclotide in Chronic Idiopathic Constipation.Vibrant系统与利那洛肽治疗慢性特发性便秘的成本效益比较
Adv Ther. 2025 Jan;42(1):310-321. doi: 10.1007/s12325-024-03035-0. Epub 2024 Nov 11.